Naproxen Sodium + Codeine Phosphate — Competitive Intelligence Brief

Naproxen Sodium + Codeine Phosphate (Naproxen Sodium + Codeine Phosphate) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID + opioid analgesic combination. Area: Pain Management.

marketed NSAID + opioid analgesic combination COX-1, COX-2, mu-opioid receptor Pain Management Small molecule

Target snapshot

Naproxen Sodium + Codeine Phosphate (Naproxen Sodium + Codeine Phosphate) — ibrahim doğru. Naproxen sodium inhibits cyclooxygenase enzymes to reduce inflammation and pain, while codeine phosphate acts as an opioid agonist to enhance analgesia through central nervous system depression.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Naproxen Sodium + Codeine Phosphate TARGET	Naproxen Sodium + Codeine Phosphate	ibrahim doğru	marketed	NSAID + opioid analgesic combination	COX-1, COX-2, mu-opioid receptor
dexketoprofen trometamol + tramadol hydrochloride	dexketoprofen trometamol + tramadol hydrochloride	Kavaklıdere Umut Hospital	marketed	NSAID + opioid analgesic combination	COX-1/COX-2 (dexketoprofen); mu-opioid receptor, norepinephrine transporter, serotonin transporter (tramadol)
Motrin and narcotic	Motrin and narcotic	Cape Fear Valley Health System	marketed	NSAID + opioid analgesic combination	COX-1/COX-2 (ibuprofen); mu, delta, and kappa opioid receptors (narcotic component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID + opioid analgesic combination class)

1. Cape Fear Valley Health System · 1 drug in this class
2. Kavaklıdere Umut Hospital · 1 drug in this class
3. ibrahim doğru · 1 drug in this class